Church & Dwight To Sell VitaFusion And L'il Critters Brands To Piping Rock

Church & Dwight has agreed to sell its VitaFusion and L'il Critters vitamins, minerals and supplements brands, including associated trademarks/licenses and manufacturing and distribution facilities in Vancouver and Ridgefield, WA, to Piping Rock Health Products; the deal is subject to customary closing conditions and is expected to close before year-end. The VMS business represents under 5% of the company’s anticipated 2025 net sales, and Church & Dwight expects to record a one-time, after-tax charge of $40–45 million in Q4 2025 to reflect net proceeds, a non-cash impairment and transition/transaction costs. The transaction effectively divests the VMS segment while monetizing assets, with a modest near-term earnings impact from the announced charge.

Analysis

Church & Dwight completed a strategic review of its vitamins, minerals and supplements (VMS) business and signed a definitive agreement to sell the VitaFusion and L'il Critters brands to Piping Rock Health Products, Inc.; the deal includes associated trademarks/licenses and the company’s manufacturing and distribution facilities in Vancouver and Ridgefield, Washington, and remains subject to customary closing conditions with expected finalization before the end of this year. The VMS brands represent less than 5% of Church & Dwight’s anticipated 2025 net sales, indicating the divestiture is a relatively small revenue reduction for the company.

The company expects a one-time, after-tax charge of $40 million to $45 million to be recorded in Q4 2025 to reflect net proceeds, a non-cash impairment, and transition and transaction-related costs; that charge creates a concentrated near-term earnings hit but is non-recurring by construction. Market signals classify sentiment as mixed and give a low market-impact score (0.15), consistent with a limited structural effect on Church & Dwight’s overall sales profile.

Strategically, the transaction monetizes non-core assets and narrows exposure to the VMS category while transferring manufacturing/distribution responsibilities to the buyer; the main execution risks are satisfying closing conditions and the final impairment/transition accounting details that will determine the ultimate cash and EPS effects. Investors should watch management disclosures on net proceeds, impairment detail and any guidance or capital-allocation updates to assess whether proceeds are deployed in shareholder-accretive ways that offset the one-time charge.

Key Decisions for Investors

• Adjust near-term earnings models to reflect a one-time after-tax charge of $40–45 million in Q4 2025 and expect a modest, concentrated EPS impact that quarter
• Treat the divestiture as largely neutral to longer-term top-line growth since the VMS brands account for under 5% of anticipated 2025 net sales and avoid overreacting to the headline sale
• Monitor closing progress, the detailed breakdown of net proceeds and impairment, and any management guidance on use of proceeds or capital allocation before changing position size
• Maintain a neutral-to-cautious stance ahead of closing and Q4 disclosures; consider trimming exposure only if disclosures indicate larger-than-expected charges or negative guidance revisions